Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar

The Federal Circuit on Friday agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent...

Already a subscriber? Click here to view full article